ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1597

Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial

Frank Behrens1, Peter Taylor2, Philip J Mease3, Paul Peloso4, Dieter Wetzel5, Nicolai Brun5, Brian Wiens6, Jan Brandt-Juergens7, Edit Drescher8, Eva Dokoupilova9, Anna Rowińska-Osuch10, Nadia Abdel- Kader Martin11 and Kurt de Vlam12, 1Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, 2University of Oxford, Oxford, United Kingdom, 3Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 4ACELYRIN, Naples, FL, 5Affibody AB, Solna, Sweden, 6ACELYRIN, Inc., Los Angeles, CA, 7Rheumatologische Schwerpunktpraxis, Berlin, Germany, 8Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary, 9Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic, 10ETG Network - Rheumatology, Warsaw, Poland, 11Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain, 12University Hospitals Leuven, Leuven, Belgium

Meeting: ACR Convergence 2022

Keywords: Biologicals, Disease Activity, Outcome measures, Psoriatic arthritis, Randomized Trial

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Session Title: Abstracts: Spondyloarthritis Including PsA – Treatment II: PsA

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations (arthritis, spondylitis, enthesitis, dactylitis, skin, nails). IL-17 inhibitors have shown efficacy across all disease domains. Izokibep, a first-in-class fusion protein, is a unique IL-17A inhibitor with very high potency (Kd =0.3 pM), small molecular size (18.6 kD versus mAbs ~ 150 kD), and attachment to albumin. Treat to target is an important strategy to optimize disease control (reducing inflammation, limiting damage) as well as optimizing quality of life in PsA. Many composite measures of disease control have been proposed for clinical decision-making, including ACR scores, DAS28-CRP, DAPSA scores, and MDA. Here, we report the efficacy results of izokibep 40 mg Q2W and 80 mg Q2W versus placebo across a range of disease outcome measures as well as relevant safety data over 16 weeks compared to placebo.

Methods: A multicenter, randomized, double-blind, placebo-controlled, study of placebo, izokibep 40 mg Q2W or 80 mg Q2W delivered subcutaneously to Week 16 (ClinicalTrials.gov, NCT04713072). PsA patients met CASPAR criteria and required ≥3 swollen and ≥3 tender joints on the 66/68 joint count, an inadequate response to previous NSAIDs, csDMARDs, or TNF inhibitors to enroll. ACR50 was the primary endpoint for izokibep 80 mg Q2W versus placebo at Week 16. Other measures of disease response included ACR20/70, DAS28-CRP, DAPSA, MDA, and PASI scores. Here we report achievement of disease activity responses over time on DAS-28CRP and DAPSA and of efficacy thresholds for MDA and PASI 75, 90, and 100.

Safety and tolerability were assessed.

Results: 135 patients were randomized at 28 sites in 7 EU countries between June 2020 and July 2021. At randomization, patients had a mean age of 48.5 years, mean BMI of 29.0 kg/m2, mean swollen joint count of 9.9, mean tender joint count of 16.7, and mean PsA duration of 7.1 years. 80% were receiving a concomitant csDMARD and 13% had failed a TNF inhibitor. At baseline, the mean DAS28-CRP was 4.51 and the mean baseline DAPSA score was 46.8. At Week 16, the primary endpoint ACR50 was met in 13% for placebo, 48% for the 40 mg Q2W group (p=0.0014), and 52% for the 80 mg Q2W group (p=0.0006). Minimal disease activity (MDA) was achieved in 42% (40mg; p=0.0020), 39% (80mg; 0.0032) versus 5% (Placebo) at Week 16 (Figure 1).

Table 1 shows treatment effects for other endpoints at Week 4 and 16. The course of the DAS28-CRP shows early response and separation from placebo, a clinically meaningful change (≥0.6) between izokibep treatment groups and placebo (Figure 2) as early as 2 weeks. Eighty-three % (40 mg), and 85% (80 mg) of patients with a PSO-BSA > 3% (74 of 135, 55%) achieved a PASI75 response versus 14% (Placebo) at Week 16.

Adverse event rates for izokibep were mostly similar to placebo and consistent with the IL-17A inhibitors currently available.

Conclusion: Izokibep showed consistently high levels of response across multiple disease measures of joint and skin improvement, beginning early and with ongoing improvement. The safety profile of izokibep was generally consistent with other IL-17A inhibitors, and in this trial, event rates were mostly similar to placebo.

Supporting image 1

Table 1 – Efficacy Composite Endpoint Results at Weeks 4 and Week 16

Supporting image 2

Figure 1 – Minimal Disease Activity (MDA) Response at Week 12 and Week 16

Supporting image 3

Figure 2 – Mean DAS28-CRP Course by Visit until Week 16 (descriptive)


Disclosures: F. Behrens, AbbVie, Boehringer Ingelheim, Celgene, Chugai, Eli Lilly, Genzyme, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, Bristol-Myers Squibb(BMS), Galapagos, Gilead, UCB, Affibody, MoonLake, GlaxoSmithKlein(GSK); P. Taylor, Biogen, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, GlaxoSmithKlein(GSK), Janssen, Nordic Pharma, Pfizer, Roche, Sanofi, UCB, Galapagos, Abbvie; P. Mease, AbbVie, Amgen, Janssen, Novartis, Pfizer Inc, UCB, Sun Pharma, Eli Lilly, Bristol-Myers Squibb(BMS), Celgene, Genentech; P. Peloso, ACELYRIN, ACELYRIN; D. Wetzel, Affibody; N. Brun, Affibody AB, Affibody AB; B. Wiens, ACELYRIN; J. Brandt-Juergens, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Janssen, Eli Lilly, Merck/MSD, Novartis, Pfizer, Roche, UCB, Sanofi-Aventis, Medac, Gilead, Gilead, Affibody; E. Drescher, None; E. Dokoupilova, None; A. Rowińska-Osuch, None; N. Abdel- Kader Martin, Pfizer; K. de Vlam, UCB, Eli Lilly, Pfizer, AbbVie/Abbott, Merck/MSD, johnson and johnson.

To cite this abstract in AMA style:

Behrens F, Taylor P, Mease P, Peloso P, Wetzel D, Brun N, Wiens B, Brandt-Juergens J, Drescher E, Dokoupilova E, Rowińska-Osuch A, Abdel- Kader Martin N, de Vlam K. Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/achievement-of-different-treatment-targets-with-izokibep-demonstrates-efficacy-benefits-in-patients-with-active-psoriatic-arthritis-results-from-a-16-week-randomized-placebo-controlled-phase-2-clini/. Accessed May 30, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/achievement-of-different-treatment-targets-with-izokibep-demonstrates-efficacy-benefits-in-patients-with-active-psoriatic-arthritis-results-from-a-16-week-randomized-placebo-controlled-phase-2-clini/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences